BSB Bancorp, Inc. (NASDAQ:BLMT)

Home >> Stock >> BSB Bancorp, Inc. >> Reports

BSB Bancorp, Inc. (BSB Bancorp), incorporated on June 2, 2011, is a bank holding company of Belmont Savings Bank (the Bank). The Company's Belmont Savings Bank is a chartered savings bank. The Bank's business consists primarily of accepting deposits from the general public, small businesses and municipalities, and investing those deposits, together with funds generated from operations and borrowings, in one- to four-family residential mortgage loans, commercial real estate loans, multi-family real estate loans, home equity lines of credit, indirect automobile loans (automobile loans assigned to it by automobile dealerships), commercial business loans, construction loans and investment securities. The Bank also makes other consumer loans and second mortgage loans. The Bank offers a range of deposit accounts, including relationship checking accounts for consumers and businesses, passbook and statement savings accounts, certificates of deposit, money market accounts, Interest on Lawyer Trust Accounts (IOLTA), commercial, municipal and regular checking accounts, and Individual Retirement Accounts (IRAs). The Bank offers a range of commercial and retail banking services, which include cash management, online and mobile banking, and global payments and foreign exchange. The Bank conducts operations from over six full service branch offices located in Belmont, Watertown, Waltham, Newton and Cambridge in Southeast Middlesex County, Massachusetts. Its primary lending market includes Essex, Middlesex, Norfolk and Suffolk Counties, Massachusetts. ...

+See More

Blog+More

Dr Chip Espinoza recommends 9 new core competences for better managing millennials in the modern workplace.

Rose Prince

2025-08-02 13:31:00 Saturday ET

Dr Chip Espinoza recommends 9 new core competences for better managing millennials in the modern workplace.

Chip Espinoza, Mick Ukleja, and Craig Rusch shine fresh light on the core competences for managing millennials as part of the new modern workforce in recent

+See More

Our fun podcasts deep-dive into the current global trends, topics, and issues in support of better stock market investment decisions.

Daphne Basel

2027-11-22 08:26:00 Monday ET

Our fun podcasts deep-dive into the current global trends, topics, and issues in support of better stock market investment decisions.

Our AYA fun podcasts deep-dive into the current global trends, topics, and issues in macro finance, political economy, public policy, strategic management,

+See More

Rakesh Jhunjhunwala is India's equivalent to Warren Buffett in America.

Jonah Whanau

2016-10-19 00:00:00 Wednesday ET

Rakesh Jhunjhunwala is India's equivalent to Warren Buffett in America.

India's equivalent to Warren Buffett in America, Rakesh Jhunjhunwala, offers several key lessons for stock market investors: When the press o

+See More

Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin, Ethereum, and Ripple.

Becky Berkman

2017-11-23 10:42:00 Thursday ET

Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin, Ethereum, and Ripple.

As the TV host of Mad Money, Jim Cramer provides 5 key reasons against the purchase and use of cryptocurrencies such as Bitcoin. First, no one knows the ano

+See More

Facebook reaches a $5 billion settlement with the Federal Trade Commission over Cambridge Analytica user privacy violations.

Monica McNeil

2019-08-12 07:30:00 Monday ET

Facebook reaches a $5 billion settlement with the Federal Trade Commission over Cambridge Analytica user privacy violations.

Facebook reaches a $5 billion settlement with the Federal Trade Commission over Cambridge Analytica user privacy violations. The Federal Trade Commission (F

+See More

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

Jacob Miramar

2019-01-10 17:31:00 Thursday ET

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history.

The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be

+See More